• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Antiviral Res . Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical s

tetano

Editor, Senior Moderator
Antiviral Res


. 2023 Jun 1;216:105639.
doi: 10.1016/j.antiviral.2023.105639. Online ahead of print. Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study

Jiayou Zhang[SUP] 1 [/SUP], Xuanxuan Nian[SUP] 1 [/SUP], Bo Liu[SUP] 1 [/SUP], Zhegang Zhang[SUP] 1 [/SUP], Wei Zhao[SUP] 1 [/SUP], Xixin Han[SUP] 1 [/SUP], Yumei Ma[SUP] 2 [/SUP], Dongwu Jin[SUP] 2 [/SUP], Hua Ma[SUP] 2 [/SUP], Qingmei Zhang[SUP] 1 [/SUP], Ran Qiu[SUP] 1 [/SUP], Fang Li[SUP] 1 [/SUP], Zheng Gong[SUP] 1 [/SUP], Xuedan Li[SUP] 1 [/SUP], Ying Yang[SUP] 3 [/SUP], Yichao Tian[SUP] 3 [/SUP], Li Zhou[SUP] 3 [/SUP], Kai Duan[SUP] 1 [/SUP], Xinguo Li[SUP] 1 [/SUP], Zhongren Ma[SUP] 4 [/SUP], Xiaoming Yang[SUP] 5 [/SUP]



Affiliations
Free article Abstract

Vaccination remains the best prevention strategy against influenza. The MDCK-based influenza vaccine prompted the development of innovative cell culture manufacturing processes. In the present study, we report the effects of multiple administrations of a candidate, seasonal, MDCK-based, quadrivalent split influenza virus vaccine MDCK-QIV in Sprague-Dawley (SD) rats. Moreover, the effects of the vaccine were evaluated in terms of fertility and early embryonic development, embryo-fetal development, and perinatal toxicity in the SD rats and immunogenicity in Wistar rats and BALB/c mice. Regarding the safety profile, MDCK-QIV demonstrated tolerance in local stimulation with repeated dose administration and presented no significant effect on the development, growth, behavior, fertility, and reproductive performance of the adult male rats, maternal rats, and their offspring. MDCK-QIV elicited strong hemagglutination inhibition neutralizing antibody response and protection against the influenza virus in the mouse model. Thus, data supported that MDCK-QIV could be further evaluated in human clinical trial, which is currently underway.

Keywords: Immunogenicity; Influenza; Madin–Darby canine kidney (MDCK) cells; Protection; Safety; Tolerance.

 
Back
Top Bottom